LEAP-006
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
- NCT03829319 ↗
- Completed
- Merck Sharp & Dohme LLC
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on LEAP-006 (lenvatinib plus pembrolizumab in first-line metastatic nonsquamous non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LEAP-006 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 12 posts on X | |
| 2 podcast episodes |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Nonsquamous Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab; Carboplatin; Cisplatin; Pemetrexed; Lenvatinib; Placebo matching lenvatinib
- Arms
- Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib · Experimental
- Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo · Placebo comparator
- Enrollment
- 761
- Primary outcomes
- Part 1: Number of Participants With a Dose-limiting Toxicity (DLT)
- Part 1: Number of Participants Who Experienced an Adverse Event (AE)
- Part 1: Number of Participants Who Discontinued Study Drug Due to an Adverse Event
- Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
- Part 2: Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC with Eisai Inc.
- Start
- Mar 25, 2019
- Primary completion
- Aug 11, 2023
- Results posted
- Yes
- Registry record
- NCT03829319 · updated Feb 5, 2026
Publications
linked from the registry- Herbst RS, Cho BC, Zhou C, Burotto M, Dols MC, Sendur MAN, Moiseyenko V, Casarini I, Nishio M, Hui R, Pons-Tostivint E, Dudnik J, Ahmed S, Okpara CE, Dutcus C, Yin L, Luo Y, Chirovsky D, Bhagwati N, Abreu DR. Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study. J Thorac Oncol. 2025 Sep;20(9):1302-1314. doi: 10.1016/j.jtho.2025.05.016. Epub 2025 May 24. PubMed 40419140